CMPS logo

COMPASS Pathways (CMPS) Stock

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

18 September 2020

Indexes:

Not included

Description:

COMPASS Pathways is a mental health care company focused on developing innovative treatments for depression and other mental health conditions. They are known for their research on psilocybin, a compound found in mushrooms, aiming to improve therapy outcomes and provide new options for patients.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

01 Nov '24 RBC Capital
Outperform
01 Nov '24 Maxim Group
Buy
01 Nov '24 HC Wainwright & Co.
Buy
10 Sept '24 RBC Capital
Outperform
09 Sept '24 Cantor Fitzgerald
Overweight
23 Aug '24 HC Wainwright & Co.
Buy
02 Aug '24 Canaccord Genuity
Buy
31 July '24 HC Wainwright & Co.
Buy
23 July '24 RBC Capital
Outperform
21 June '24 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Psychedelic Stocks: Focus On Their Cash
Psychedelic Stocks: Focus On Their Cash
Psychedelic Stocks: Focus On Their Cash
CMPS
seekingalpha.com15 August 2024

Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.

COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
CMPS
seekingalpha.com04 August 2024

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Ritu Baral - TD Cowen Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Vikram Purohit - Morgan Stanley Gavin Clark-Gartner - Evercore ISI Sumant Kulkarni - Canaccord Genuity Tom Shrader - BTIG Elemer Piros - Rodman Operator Good day, ladies and gentlemen, and welcome to COMPASS Pathways' Second Quarter 2024 Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Compass Pathways to announce first quarter financial results on May 8, 2024
Compass Pathways to announce first quarter financial results on May 8, 2024
Compass Pathways to announce first quarter financial results on May 8, 2024
CMPS
GlobeNewsWire03 May 2024

Compass Pathways plc, a biotechnology company focused on improving patient access to evidence-based mental health solutions, will report its financial results for the first quarter of 2024 and share recent business updates on May 8, 2024.

Penny Power Players: 3 Stocks to Watch in the Microcap Arena
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
CMPS
InvestorPlace27 February 2024

There are some great microcap stocks for investors to scoop up this month. The broader indices, such as the S&P 500 and the Nasdaq, are showing signs of both strength and weakness, but I believe that there's still a lot of gas left in the tank for these to surge higher.

Compass Pathways to participate in upcoming TD Cowen investor conference
Compass Pathways to participate in upcoming TD Cowen investor conference
Compass Pathways to participate in upcoming TD Cowen investor conference
CMPS
GlobeNewsWire26 February 2024

LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference at 12:50 pm ET on March 4, 2024.

Compass Pathways to participate in upcoming Oppenheimer investor conference
Compass Pathways to participate in upcoming Oppenheimer investor conference
Compass Pathways to participate in upcoming Oppenheimer investor conference
CMPS
GlobeNewsWire31 January 2024

LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference at 2:00 pm ET on February 13, 2024.

De-Risking Psychedelics: Compass Pathways, Cybin And Atai
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
CMPS
Seeking Alpha09 January 2024

Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.

COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript
CMPS
Seeking Alpha04 November 2023

COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Ritu Baral - TD Cohen Charles Duncan - Cantor François Brisebois - Oppenheimer Patrick Trucchio - H.C. Wainright Michael Okunewitch - Maxim Group Sumant Kulkarni - Canaccord Genuity Gavin Clark-Gartner - Evercore ISI Thomas Shrader - BTIG Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2023 Conference Call.

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
CMPS
GlobeNewsWire24 October 2023

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.

Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
CMPS
InvestorPlace27 September 2023

Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of COMPASS Pathways?
  • What is the ticker symbol for COMPASS Pathways?
  • Does COMPASS Pathways pay dividends?
  • What sector is COMPASS Pathways in?
  • What industry is COMPASS Pathways in?
  • What country is COMPASS Pathways based in?
  • When did COMPASS Pathways go public?
  • Is COMPASS Pathways in the S&P 500?
  • Is COMPASS Pathways in the NASDAQ 100?
  • Is COMPASS Pathways in the Dow Jones?
  • When was COMPASS Pathways's last earnings report?
  • When does COMPASS Pathways report earnings?
  • Should I buy COMPASS Pathways stock now?

What is the primary business of COMPASS Pathways?

COMPASS Pathways is a mental health care company focused on developing innovative treatments for depression and other mental health conditions. They are known for their research on psilocybin, a compound found in mushrooms, aiming to improve therapy outcomes and provide new options for patients.

What is the ticker symbol for COMPASS Pathways?

The ticker symbol for COMPASS Pathways is NASDAQ:CMPS

Does COMPASS Pathways pay dividends?

No, COMPASS Pathways does not pay dividends

What sector is COMPASS Pathways in?

COMPASS Pathways is in the Healthcare sector

What industry is COMPASS Pathways in?

COMPASS Pathways is in the Medical Care Facilities industry

What country is COMPASS Pathways based in?

COMPASS Pathways is headquartered in United Kingdom

When did COMPASS Pathways go public?

COMPASS Pathways's initial public offering (IPO) was on 18 September 2020

Is COMPASS Pathways in the S&P 500?

No, COMPASS Pathways is not included in the S&P 500 index

Is COMPASS Pathways in the NASDAQ 100?

No, COMPASS Pathways is not included in the NASDAQ 100 index

Is COMPASS Pathways in the Dow Jones?

No, COMPASS Pathways is not included in the Dow Jones index

When was COMPASS Pathways's last earnings report?

COMPASS Pathways's most recent earnings report was on 31 October 2024

When does COMPASS Pathways report earnings?

The next expected earnings date for COMPASS Pathways is 28 February 2025

Should I buy COMPASS Pathways stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions